Growth hormone study for short kids halted early

NCT ID NCT00597480

Terminated Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at two ways of giving growth hormone to short children who were born small for their age. The goal was to see which dosing method works better for growth and has fewer side effects on metabolism. Only 10 children took part before the study was stopped early.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: recombinant growth hormone (rhGH)
What this could lead to: If successful, this study could help identify the best dosing strategy to improve height while minimizing metabolic risks like insulin resistance.
What could go wrong: This was a small, terminated Phase 4 trial with only 10 participants, so results may not be reliable or generalizable. Growth hormone can increase insulin levels, raising concerns about future diabetes risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL FOR GESTATIONAL AGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fetal growth restriction Insulin Resistance metabolic syndrome X

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SMALL FOR GESTATIONAL AGE

Contacts and locations

Locations

Hopital Saint Vincent de Paul

Paris, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.